Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1305 is a non-coding RNA transcript (3122 bp, three exons), located on the forward strand of chromosome 2. It does not encode a protein but is primarily expressed in the cytosol and exosomes of tumor cells. LINC01305 is notably upregulated in cervical cancer and esophageal squamous cell carcinoma tissues, where it promotes cell proliferation, migration, invasion, and inhibits apoptosis. It exerts its effects by interacting with RNA-binding proteins (such as KHSRP and BNC1) and regulates critical signaling pathways (JNK and Wnt) related to EMT, stemness, and tumor progression. High expression of LINC01305 is associated with poor clinical prognosis and may serve both as a biomarker and as a potential therapeutic target in oncology.
When targeted, inhibition or knockdown of LINC01305 leads to reduced tumor growth, decreased proliferation, and increased apoptosis. Its oncogenic effects are mediated by interaction with protein partners (KHSRP, BNC1), impacting transcriptional and signaling pathways (e.g., PI3K/Akt, JNK/EMT).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1305 (LINC01305).